Did you mean "hepatitis"?
Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response | ACP Gastroenterology Monthly
A commentary in ACP Journal Club noted that while screening and treating all patients with chronic hepatitis C virus (HCV) would be cost-effective and probably cost-saving, some payers are still resistant.
ACP and the American Academy of HIV Medicine collaborate on new guide to hepatitis C testing | ACP Gastroenterology Monthly
The guide includes a summary of the latest testing recommendations; diagnostic, billing, and laboratory codes for testing; resources for referrals to HCV-experienced clinicians; and information on patient interactions, education, conversations, and
Reformulation of extended-release oxycodone may have triggered increase in hepatitis C rates | ACP Gastroenterology Monthly
Hepatitis C virus infections increased three times faster in states with above-median rates of initial misuse of extended-release oxycodone (OxyContin) than in states with below-median rates, and the increase began immediately after a reformulation
This month's quiz asks readers to evaluate a 58-year-old man at a follow-up visit for hepatitis C-related cirrhosis complicated by nonbleeding small esophageal varices and ascites.
8 weeks of ledipasvir/sofosbuvir may be effective for genotype 1 hepatitis C | ACP Gastroenterology Monthly
The therapy should be considered in patients with genotype 1 infection who are treatment-naive, do not have cirrhosis, and have a pretreatment viral load below 6,000,000 IU/mL, a study found.
ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.
High HCV cure rate seen with FDA-approved direct-acting antiviral regimens | ACP Gastroenterology Monthly
Six of the direct-acting antiviral (DAA) regimens yielded sustained virologic response rates above 95% in patients who had hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with HIV co-infection.
HCV treatment appeared successful for patients who hadn't responded to previous direct-acting antivirals, industry-funded study finds | ACP Gastroenterology Monthly
The study included two phase 3 trials: POLARIS-1, in which patients with chronic hepatitis C virus (HCV) had previously taken a regimen containing an NS5A inhibitor, and POLARIS-4, in which patients had previously received a direct-acting antiviral
Studies of contemporary populations with hepatitis C virus infection demonstrated that treatment with direct-acting antiviral therapies was linked to improvement in several long-term clinical outcomes.
Transplant of HCV-infected kidneys to HCV-negative recipients yields good outcomes at 12 months | ACP Gastroenterology Monthly
The study authors concluded that their results should encourage efforts to increase use of hepatitis C virus (HCV)-infected kidneys and called for larger confirmatory trials.